Drug Type Antibody drug conjugate (ADC), Biosimilar |
Synonyms 恩美曲妥珠单抗生物类似药(Defence) + [1] |
Target |
Mechanism HER2 antagonists(Receptor protein-tyrosine kinase erbB-2 antagonists), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC35H48ClN3O10S |
InChIKeyANZJBCHSOXCCRQ-FKUXLPTCSA-N |
CAS Registry139504-50-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | - | - |